Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback